- Home
- SI vs BNR Comparison
SI vs BNR Comparison
Compare SI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | BNR |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 252.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SI | BNR |
|---|---|---|
| Price | $13.74 | $17.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.80 | N/A |
| AVG Volume (30 Days) | ★ 54.7K | 19.0K |
| Earning Date | 05-13-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.59 | $111.65 |
| Revenue Next Year | $31.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.92 | $2.49 |
| 52 Week High | $17.23 | $41.72 |
Technical Indicators
Market Signals| Indicator | SI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 38.00 |
| Support Level | $13.47 | $15.57 |
| Resistance Level | $13.63 | $23.19 |
| Average True Range (ATR) | 0.82 | 1.33 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 74.82 | 10.54 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.